Innovent licenses IBI355 rights to Spero for up to $1.1bn

Innovent Biologics has granted Spero Therapeutics an exclusive licence deal to develop and commercialise IBI355 outside Greater China. Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan. IBI355 targets CD40L, an immune signal protein involved in multiple immune pathways and immune-mediated diseases. Credit: THICHA SATAPITANON / Shutterstock.com. Innovent Biologics has agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to develop, research, manufacture and commercialise IBI355, also known as SP001, outside Greater China. IBI355 is an Fc-silent, third-generation anti-CD40L antibody that is expected to…

Source: Pharmaceutical Technology